Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Annals of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDG029PMID 12488300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine

  2004cited by this paper
• A single institution experience

  2003cited by this paper
• Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.

  2002cited by this paper
• Present and future treatment of pancreatic cancer.

  2002cited by this paper
• Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.

  2002cited by this paper
• Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

  2002cited by this paper
• Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.

  2001cited by this paper
• Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.

  2001cited by this paper
• Gemcitabine (GEM) and capecitabine (CAP) for advanced pancreatic cancer. A phase I/II trial

  2001cited by this paper
• Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.

  2001cited by this paper
• Combination Gemcitabine and Docetaxel Therapy in Advanced Adenocarcinoma of the Pancreas

  2001cited by this paper
• Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).

  2001cited by this paper
• A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

  2000cited by this paper
• A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer.

  2000cited by this paper
• Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.

  2000cited by this paper
• A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

  2000cited by this paper
• Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

  1999cited by this paper
• [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].

  1999cited by this paper
• Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells.

  1998cited by this paper
• Cancer statistics, 1998

  1998cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• [Chemotherapy for adenocarcinoma of the pancreas].

  1997cited by this paper
• Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.

  1997cited by this paper
• Chemotherapy of adenocarcinoma of the pancreas.

  1996cited by this paper
• Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.

  1996cited by this paper
• Chemotherapy of adenocarcinoma of the pancreas.

  1996cited by this paper
• Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.

  1995cited by this paper
• Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994.

  1995cited by this paper
• Gemcitabine in non-small cell lung cancer.

  1995cited by this paper
• Introduction: Gemcitabine - Status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog

  1995cited by this paper
• Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

  1994cited by this paper
• Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

  1994cited by this paper
• Confirmatory activity of gemcitabine in non small cell lung cancer (NSCLC)

  1993cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• In Japan …

  1975cited by this paper
• Reporting results.

  1969cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Some Methods for Strengthening the Common χ 2 Tests

  1954cited by this paper

• S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1

  2024cites this paper
• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2024cites this paper
• Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma.

  2024cites this paper
• Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort study

  2023cites this paper
• The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis

  2022cites this paper
• Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer

  2021cites this paper
• STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer

  2021cites this paper
• Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain.

  2021cites this paper
• Chemotherapy for Advanced Pancreatic Cancer: Available Drugs, Mechanisms and Toxicity

  2021cites this paper
• Chemotherapy for Nonresectable Pancreatic Cancer

  2021cites this paper
• Medikamentöse Therapie des Pankreaskarzinoms: Was gibt es Neues?

  2020influential citation
• Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.

  2020cites this paper
• Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse

  2019cites this paper
• Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer.

  2019cites this paper
• Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).

  2019cites this paper
• Capecitabine for the treatment of pancreatic cancer

  2019cites this paper
• Medikamentöse Therapie des Pankreaskarzinoms: Was gibt es Neues?

  2019cites this paper
• Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016

  2019cites this paper
• Medikamentöse Therapie des Pankreaskarzinoms: Was gibt es Neues?

  2019influential citation
• Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions

  2019cites this paper
• Folfirinox Neoadjuvant Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer - A Retrospective Study

  2019cites this paper
• Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis

  2018cites this paper
• Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta‐analysis

  2018influential citation
• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2018cites this paper
• An Array of Bioactive Compounds From Australian Eucalypts and Their Relevance in Pancreatic Cancer Therapeutics

  2018cites this paper
• Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta‐analysis

  2018cites this paper
• A pilot study investigating specific immune regulatory cells and microRNA in patients with advanced Pancreatic Adenocarcinoma treated with intravenous omega-3 fish oil infusion and Gemcitabine

  2018cites this paper
• Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

  2018cites this paper
• The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis

  2018cites this paper
• Medikamentöse Therapie des Pankreaskarzinoms: Was gibt es Neues?

  2018cites this paper
• Pancreatic cancer: treatment approaches and trends

  2018cites this paper
• Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)

  2018cites this paper
• Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis

  2017cites this paper
• Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

  2017cites this paper
• Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial

  2017cites this paper
• EVALUATION OF INTRA-ARTERIAL CHEMOTHERAPY SAFETY BY USING OF GEMCITABINE AND OXALIPLATIN IN COMBINED TREATMENT OF PANCREATIC HEAD ADENOCARCINOMA

  2017cites this paper
• Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System.

  2017cites this paper
• Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.

  2016cites this paper
• Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

  2016cites this paper
• Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer.

  2016cites this paper
• Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma.

  2016cites this paper
• Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

  2016cites this paper
• Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.

  2015cites this paper
• Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers

  2015cites this paper
• Advanced pancreatic cancer - how to choose an adequate treatment option.

  2015cites this paper
• Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma

  2015cites this paper
• Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104

  2015cites this paper
• Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

  2015cites this paper
• An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?

  2015cites this paper
• Bioequivalence of Two Formulations (Innovator vs Generic) of Capecitabine in Patients with Cancer of Colon

  2015cites this paper
• Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy

  2015cites this paper
• The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.

  2015cites this paper
• Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials.

  2015cites this paper
• Recent advances in pancreatic cancer: biology, treatment, and prevention.

  2015cites this paper
• The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure.

  2015cites this paper
• Multimodal Therapies for Pancreatic Cancer

  2014cites this paper
• A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics.

  2014cites this paper
• A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer

  2014cites this paper
• Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.

  2014cites this paper
• Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials

  2014cites this paper
• Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.

  2014cites this paper
• Author ' s response to reviews Title : Chemotherapy for advanced pancreatic cancer : A systematic review and network meta-analysis

  2014cites this paper
• Delivering curcumin and gemcitabine in one nanoparticle platform for colon cancer therapy

  2014cites this paper
• Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis

  2014cites this paper
• Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer

  2014cites this paper
• Cancer Chemotherapy Update Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer

  2014cites this paper
• Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel

  2014cites this paper
• FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience

  2013cites this paper
• Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).

  2013cites this paper
• Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/ cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study

  2013cites this paper
• Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer

  2013cites this paper
• Manganoporphyrins as adjuvants to enhance pharmacological ascorbate in pancreatic cancer therapy

  2013cites this paper
• Metformin and Survival in Pancreatic Cancer: A Retrospective Cohort Study

  2013cites this paper
• Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer

  2013cites this paper
• Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis

  2013cites this paper
• Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

  2013cites this paper
• Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer: A Trend Analysis Using the Surveillance, Epidemiology, and End Results Registry From 1988 to 2008

  2013cites this paper
• Systemische und regionale Chemotherapie beim fortgeschrittenen und metastasierten Pankreaskarzinom

  2013cites this paper
• Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.

  2013cites this paper
• Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

  2012cites this paper
• A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer

  2012cites this paper
• Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced Pancreatic and Biliary Carcinomas

  2012cites this paper
• Pancreatic cancer: medical management (novel chemotherapeutics).

  2012cites this paper
• Intraperitoneal gemcitabine chemotherapy as an adjuvant treatment for patients with resected pancreatic cancer: Phase II and pharmacologic studies

  2012cites this paper
• Conventional chemotherapy of advanced pancreatic cancer.

  2012cites this paper
• Treatment options for advanced pancreatic cancer

  2012cites this paper
• Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?

  2012cites this paper
• Treatment options for advanced pancreatic cancer: a review

  2012cites this paper
• Emerging therapeutic options for metastatic exocrine pancreatic cancer

  2012cites this paper
• Chapter 63A – Chemotherapy and radiotherapy for pancreatic and periampullary cancer: Adjuvant, neoadjuvant, and palliative

  2012cites this paper
• Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation.

  2012cites this paper
• A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer

  2012cites this paper
• [Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis].

  2011cites this paper
• [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].

  2011cites this paper
• Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.

  2011cites this paper
• Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data

  2011cites this paper
• Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells

  2011cites this paper
• A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

  2011cites this paper
• Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy.

  2011cites this paper
• Unresectable Pancreatic Cancer

  2011cites this paper